Cognis/IMD alliance yields first material
Following the signing of a cooperation agreement between Cognis and InterMed Discovery (IMD) in March this year, Cognis has exclusively licensed an anti-obesity product candidate from IMD’s advanced discovery pipeline of functional food ingredients.
Following the signing of a cooperation agreement between Cognis and InterMed Discovery (IMD) in March this year, Cognis has exclusively licensed an anti-obesity product candidate from IMD’s advanced discovery pipeline of functional food ingredients.
The ingredient has shown safety and efficacy in animal studies and Cognis will now set up first human studies.
Commenting on the transaction, Norbert Weitkemper said: “We believe that active ingredients promoting weight management through functional food have a unique selling potential in the consumer market. By licensing this active ingredient we are strengthening our product portfolio in this important growth market. Further ingredients from IMD matching our customers’ market demands are still in the exploration phase.”